| Name | N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide |
|---|---|
| Synonyms | N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide,hydrochloride |
| Description | PHA-543613 is a potent, orally active, brain-penetrant and selective α7 nAChR agonist with a Ki of 8.8 nM. PHA-543613 displays selectivity for α7-nAChR over α3β4, α1β1γδ, α4β2 and 5-HT3 receptors[1]. PHA-543613 can be used for the cognitive deficits of Alzheimer's disease and schizophrenia research[2]. |
|---|---|
| Related Catalog | |
| Target |
Ki: 8.8 nM (α7 nAChR)[1] |
| In Vivo | PHA-543613 (0.3 mg/kg) successfully reverses Scopolamine-induced short-term memory deficits in rats[2]. |
| References |
| Molecular Formula | C15H17N3O2 |
|---|---|
| Molecular Weight | 271.31 |
| Exact Mass | 307.10900 |
| PSA | 58.37000 |
| LogP | 2.78260 |
| RIDADR | NONH for all modes of transport |
|---|
| Precursor 9 | |
|---|---|
| DownStream 0 | |